|Last Price$12.10||Day Change (%)1.68%|
|Open Price$11.88||Day Change ($)0.20|
|Day Range11.88–12.25||52-Week Range6.00–13.18|
As of Thu 8/25/2016 5:00:00 PM | USD
Cytokinetics' CYTK ispinesib trial results for head and neck cancer did not yield a statistically significant change in its patients. We are leaving our fair value estimate at $3.50 per share, as we had already assigned a low probability of success for this indication. Our more conservative ...
Cytokinetics faces challenging odds.